{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"163"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"237"},{"groupId":"OG001","value":"232"}],"units":"Participants"}],"description":"The number of patients experiencing grade 3 or higher toxicity (adverse events considered at least possibly related to treatment) is reported below.","groups":[{"description":"Patients receive gemcitabine hydrochloride and cisplatin as in arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm II (GCB)"},{"description":"Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and cisplatin IV and placebo IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive placebo IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm I (GCP)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients who started treatment are evaluable for adverse events.","reportingStatus":"POSTED","timeFrame":"Up to 7 years","title":"Number of Patients Experiencing Grade 3+ Toxicity","type":"SECONDARY","unitOfMeasure":"Participants"}